Evidence map›Paper›PMID 29214221›Full record

ArticleClinical medical reviews and case reports2016

Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.

Lucien L Duquette, Frank Mattiace, Kenneth Blum, Roger L Waite, Teresa Boland, Thomas McLaughlin, Kristina Dushaj, Marcelo Febo, Rajendra D Badgaiyan

Open access · hybridAbstract read
In one paragraph

Article in Clinical medical reviews and case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lucien L DuquetteNew Pathway Counseling Services Inc., Paramus, NJ, USA.
Frank MattiaceNew Pathway Counseling Services Inc., Paramus, NJ, USA.
Kenneth BlumDepartment of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA.
Roger L WaiteDepartment of Nutrigenomic Translational Research, LaVita RDS, Salt Lake City, UT, USA.
Teresa BolandTotal Health Solutions, Inc., Miami Beach, FL, USA.
Thomas McLaughlinCenter for Psychiatric Medicine, North Andover, MA, USA.
Kristina DushajDepartment of Clinical Neurology, PATH Foundation NY, New York, NY, USA.
Marcelo FeboDepartment of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA.
Rajendra D BadgaiyanDepartment of Psychiatry, Laboratory of Molecular and Functional Imaging, University of Minnesota, Minneapolis, MN, USA.
Englewood Hospital and Medical Center · US

Funding

Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
Brain Imaging of Cocaine and Maternal RewardR01DA019946 · NIDA · UNIVERSITY OF FLORIDA · PI FEBO, MARCELO · 2007 to 2011
$1.6M
Detection of Dopamine Release During a Cognitive TaskR21MH073624 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI BADGAIYAN, RAJENDRA D · 2005 to 2006
$368k
NIDA NIH HHS R01 DA019946NIMH NIH HHS R21 MH073624NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

backgroundWith neurogenetic and epigenetic tools utilized in research and neuroimaging, we are unraveling the mysteries of brain function, especially as it relates to Reward Deficiency (RDS). We encourage the development of pharmaceuticals or nutraceuticals that promote a reduction in dopamine resistance and balance brain neurochemistry, leading to dopamine homeostasis. We disclose self-assessment of a highly functional professional under work-related stress following KB220Z use, a liquid (aqua) nano glutaminergic-dopaminergic optimization complex (GDOC). CASE PRESENTATION: Subject took GDOC for one month. Subject self-administered GDOC using one-half-ounce twice a day. During first three days, unique brain activation occurred; resembling white noise after 30 minutes and sensation was strong for 45 minutes and then dissipated. He described effect as if his eyesight improved slightly and pointed out that his sense of smell and sleep greatly improved. Subject experienced a calming effect similar to meditation that could be linked to dopamine release. He also reported control of going over the edge after a hard day's work, which was coupled with a slight increase in energy, increased motivation to work, increased focus and multi-tasking, with clearer purpose of task at hand. Subject felt less inhibited in a social setting and suggested Syndrome that GDOC increased his Behavior Activating System (reward), while having a decrease in the Behavior Inhibition System (caution).

conclusionThese results and other related studies reveal an improved mood, work-related focus, and sleep. These effects as a subjective feeling of brain activation maybe due to direct or indirect dopaminergic interaction. While this case is encouraging, we must await more research in a larger randomized placebo-controlled study to map the role of GDOC, especially in a nano-sized product, to determine the possible effects on circuit inhibitory control and memory banks and the induction of dopamine homeostasis independent of either hypo- or hyper-dopaminergic traits/states.

Indexed as

DopaminergicFocusGlutaminergicKB220z-nano-liquid VariantMotivationReward Deficiency Syndrome (RDS)Sensory input

Identifiers

PMID29214221
PMCPMC5714519
OpenAlexW2584331419

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.